Journal of Clinical Oncology, Vol 15, 2596-2603, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma

SA Grossman, M Wharam, V Sheidler, L Kleinberg, M Zeltzman, N Yue and S Piantadosi
The Johns Hopkins Medical Institutions, Baltimore, MD, USA. grossman@welchlink.welch.jhu.edu

PURPOSE: To evaluate the activity and toxicity of carmustine (BCNU) and cisplatin administered as a 72-hour continuous intravenous infusion before radiation in adults with newly diagnosed high-grade astrocytomas. PATIENTS AND METHODS: Fifty-two patients with a Karnofsky performance status greater than 60 and no prior antineoplastic therapy entered this protocol. The median age of the patients was 55 years. Eighty-eight percent had glioblastoma multiforme and 12% had anaplastic astrocytomas. BCNU (40 mg/m2/d) and cisplatin (40 mg/m2/d) were administered concurrently as a 72-hour infusion every 3 to 4 weeks. Radiation was begun 4 weeks after the third cycle of chemotherapy or earlier for progressive disease. Responses required a > or = 50% reduction in contrast-enhancing volume. RESULTS: Forty patients (77%) completed three chemotherapy infusions, five (10%) received two infusions, and seven (13%) received only one. Fifty-one patients completed radiation. Seventeen (42%) patients with measurable disease had a partial response (PR) to chemotherapy, 23 (53%) had stable disease (SD), and two (4%) had progressive disease (PD) on chemotherapy. The median survival time for all patients was 13 months. Survival rates at 1, 2, 3, and 5 years were 62%, 19%, 12%, and 5%, respectively. Grade III to IV leukopenia occurred in 32% of patients; 63% received platelet transfusions and 58% required RBCs. Neutropenic fevers were rare and no intracranial hemorrhages or treatment-related deaths were noted. Nausea, vomiting, peripheral neuropathy, hearing loss, and thromboembolic events were relatively common. CONCLUSION: This chemotherapy regimen appears to have significant activity and may prolong survival in adults with newly diagnosed high-grade astrocytoma.

This article has been cited by other articles:

				D. Frappaz, M. Schell, P. Thiesse, P. Marec-Berard, C. Mottolese, D. Perol, C. Bergeron, T. Philip, A. C. Ricci, S. Galand-Desme, et al. Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: Final results of BSG 98 prospective trial Neuro-oncol, August 1, 2008; 10(4): 599 - 607. [Abstract] [Full Text] [PDF]

				O. L. Chinot, M. Barrie, S. Fuentes, N. Eudes, S. Lancelot, P. Metellus, X. Muracciole, D. Braguer, L. Ouafik, P.-M. Martin, et al. Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide J. Clin. Oncol., April 20, 2007; 25(12): 1470 - 1475. [Abstract] [Full Text] [PDF]

				M. R. Gilbert New treatments for malignant gliomas: careful evaluation and cautious optimism required. Ann Intern Med, March 7, 2006; 144(5): 371 - 373. [Full Text] [PDF]

				M. Barrie, C. Couprie, H. Dufour, D. Figarella-Branger, X. Muracciole, K. Hoang-Xuan, D. Braguer, P. M. Martin, J. C. Peragut, F. Grisoli, et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme Ann. Onc., July 1, 2005; 16(7): 1177 - 1184. [Abstract] [Full Text] [PDF]

				M. Brada, S. Ashley, A. Dowe, A. Gonsalves, A. Huchet, G. Pesce, M. Reni, F. Saran, B. Wharram, M. Wilkins, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide Ann. Onc., June 1, 2005; 16(6): 942 - 949. [Abstract] [Full Text] [PDF]

				D. A. Reardon, J. A. Quinn, J. N. Rich, S. Gururangan, J. Vredenburgh, J. H. Sampson, J. M. Provenzale, A. Walker, M. Badruddoja, S. Tourt-Uhlig, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma Neuro-oncol, April 1, 2004; 6(2): 134 - 144. [Abstract] [PDF]

				S. A. Grossman, A. O'Neill, M. Grunnet, M. Mehta, J. L. Pearlman, H. Wagner, M. Gilbert, H. B. Newton, and R. Hellman Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394 J. Clin. Oncol., April 15, 2003; 21(8): 1485 - 1491. [Abstract] [Full Text] [PDF]

				B. N. Joe, M. B. Fukui, C. C. Meltzer, Q.-s. Huang, R. S. Day, P. J. Greer, and M. E. Bozik Brain Tumor Volume Measurement: Comparison of Manual and Semiautomated Methods Radiology, September 1, 1999; 212(3): 811 - 816. [Abstract] [Full Text]

				V. A. Levin Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are heading Neuro-oncol, January 1, 1999; 1(1): 69 - 80. [Abstract] [PDF]